Specialty Infusion Medications
Amvuttra (vutrisiran)
Indication: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Administration: Subcutaneous injection
Infusion Duration: Injection takes a few minutes.
Frequency: Once every 3 months.
Avsola (infliximab-axxq)
Indication: Treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Administration: Intravenous (IV) infusion
Infusion Duration: At least a 2-hour period.
Frequency: Weeks 0, 2, and 6; then every 8 weeks.
Benlysta (belimumab)
Indication: Systemic lupus erythematosus and lupus nephritis.
Administration: Intravenous (IV) infusion
Infusion Duration: Approximately 1 hour.
Frequency: Loading: 3 infusions over 6 weeks; Maintenance: every 4 weeks.
Cerezyme (imiglucerase)
Indication: Enzyme replacement therapy for Type 1 Gaucher disease.
Administration: Intravenous infusion
Infusion Duration: 1 to 2 hours.
Frequency: Every 2 weeks.
Cuvitru (immune globulin subcutaneous)
Indication: Treatment of primary immunodeficiency (PI) in adults and children.
Administration: Subcutaneous infusion
Infusion Duration: About 15 minutes (after initial infusions).
Frequency: Typically weekly.
Entyvio (vedolizumab)
Indication: Moderate to severe ulcerative colitis and Crohn’s disease.
Administration: Intravenous infusion
Infusion Duration: 30 minutes.
Frequency: Weeks 0, 2, 6 (induction); then every 8 weeks.
Evenity (romosozumab-aqqg)
Indication: Osteoporosis in postmenopausal women at high risk for fracture.
Administration: Subcutaneous injection
Infusion Duration: Administered as two consecutive subcutaneous injections.
Frequency: Once monthly for 12 months.
Fabrazyme (agalsidase beta)
Indication: Enzyme replacement for Fabry disease.
Administration: Intravenous infusion
Infusion Duration: Varies based on dose and tolerance (initial rate: 0.25 mg/min).
Frequency: Every 2 weeks.
Gammagard Liquid (immune globulin intravenous)
Indication: Primary immunodeficiency (PI) and multifocal motor neuropathy (MMN).
Administration: Intravenous infusion
Infusion Duration: Initial rate: 0.5 mL/kg/hr for 30 mins; may be increased as tolerated.
Frequency: Typically every 3 to 4 weeks.
Gammaplex (immune globulin intravenous)
Indication: Primary immunodeficiency and chronic ITP.
Administration: Intravenous infusion
Infusion Duration: Infusion rate increases every 15 mins to reduce duration.
Frequency: Every 3 to 4 weeks.
Gamunex-C (immune globulin)
Indication: Primary immunodeficiency, CIDP, and ITP.
Administration: Intravenous infusion
Infusion Duration: Average infusion time: ~2.7 hours.
Frequency: Every 3 to 4 weeks.
Hizentra
Indication: Primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Administration: Subcutaneous infusion
Infusion Duration: 1.6 to 2.0 hours (median).
Frequency: Weekly or biweekly based on patient needs.
HyQvia
Indication: Primary immunodeficiency (PI) in adults.
Administration: Subcutaneous infusion
Infusion Duration: Several hours initially; may decrease over time.
Frequency: Every 3 to 4 weeks.
Inflectra
Indication: Autoimmune diseases like RA, Crohn’s disease, and ulcerative colitis.
Administration: Intravenous infusion
Infusion Duration: At least 2 hours.
Frequency: Induction: Weeks 0, 2, and 6; then every 8 weeks.
Infliximab
Indication: Autoimmune diseases such as RA, Crohn’s disease, and ulcerative colitis.
Administration: Intravenous infusion
Infusion Duration: At least 2 hours.
Frequency: Weeks 0, 2, and 6; then every 8 weeks.
Injectafer (ferric carboxymaltose)
Indication: Iron deficiency anemia in adults with CKD or intolerance to oral iron.
Administration: Intravenous infusion or slow IV push
Infusion Duration: At least 15 minutes when diluted and infused.
Frequency: Two doses, at least 7 days apart.
IVIG (Intravenous Immunoglobulin)
Indication: Primary immunodeficiency and autoimmune conditions.
Administration: Intravenous infusion
Infusion Duration: Typically 2 to 4 hours.
Frequency: Every 3 to 4 weeks.
Krystexxa (pegloticase)
Indication: Chronic gout in adults refractory to conventional therapy.
Administration: Intravenous infusion
Infusion Duration: Administered over no less than 2 hours.
Frequency: Every 2 weeks.
Nexviazyme (avalglucosidase alfa-ngpt)
Indication: Late-onset Pompe disease in patients ≥1 year old.
Administration: Intravenous infusion
Infusion Duration: 4 to 5 hours.
Frequency: Every 2 weeks.
Nulojix (belatacept)
Indication: Prophylaxis of organ rejection in adult kidney transplant recipients.
Administration: Intravenous infusion
Infusion Duration: 30 minutes.
Frequency: Days 1, 5, and at the end of weeks 2, 4, 8, 12; then every 4 weeks.
Ocrevus (ocrelizumab)
Indication: Relapsing and primary progressive multiple sclerosis.
Administration: Intravenous infusion
Infusion Duration: 2.5 to 3.5 hours depending on dose.
Frequency: Initial 2 infusions 2 weeks apart, then every 6 months.
Octagam
Indication: Primary immunodeficiency and chronic ITP.
Administration: Intravenous infusion
Infusion Duration: Varies with tolerance; infusion rate adjusted incrementally.
Frequency: Every 3 to 4 weeks.
Onpattro (patisiran)
Indication: Polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Administration: Intravenous infusion
Infusion Duration: Approx. 80 minutes.
Frequency: Every 3 weeks.
Orencia (abatacept)
Indication: RA, juvenile idiopathic arthritis, and psoriatic arthritis.
Administration: IV infusion or subcutaneous injection
Infusion Duration: Approx. 30 minutes (IV).
Frequency: IV: Weeks 0, 2, 4, then every 4 weeks.
Privigen
Indication: Primary humoral immunodeficiency and chronic ITP.
Administration: Intravenous infusion
Infusion Duration: Varies with dose; infusion rate is increased gradually.
Frequency: Every 3 to 4 weeks.
Remicade
Indication: RA, Crohn’s disease, ulcerative colitis, and other autoimmune diseases.
Administration: Intravenous infusion
Infusion Duration: At least 2 hours.
Frequency: Induction: Weeks 0, 2, and 6; then every 8 weeks.
Renflexis
Indication: Autoimmune conditions such as RA, UC, and Crohn’s disease.
Administration: Intravenous infusion
Infusion Duration: At least 2 hours.
Frequency: Induction: Weeks 0, 2, and 6; then every 8 weeks.
Rituxan
Indication: RA, GPA, MPA, and some cancers.
Administration: Intravenous infusion
Infusion Duration: Varies with indication; initial rate 50 mg/h increased as tolerated.
Frequency: RA: 2 doses 2 weeks apart; then as needed.
Saphnelo
Indication: Moderate to severe systemic lupus erythematosus (SLE).
Administration: Intravenous infusion
Infusion Duration: 30 minutes.
Frequency: Every 4 weeks.
Simponi Aria
Indication: Moderately to severely active RA, PsA, and AS.
Administration: Intravenous infusion
Infusion Duration: 30 minutes.
Frequency: Weeks 0 and 4; then every 8 weeks.
Skyrizi
Indication: Moderate to severe plaque psoriasis and psoriatic arthritis.
Administration: Subcutaneous injection
Infusion Duration: Quick injection (no infusion).
Frequency: Weeks 0, 4, 8; then every 12 weeks.
Stelara
Indication: Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis.
Administration: IV infusion (CD/UC); SC for others
Infusion Duration: IV: At least 1 hour.
Frequency: IV induction; SC every 8 weeks for maintenance.
Tysabri
Indication: Multiple sclerosis and Crohn’s disease.
Administration: Intravenous infusion
Infusion Duration: 1 hour.
Frequency: Every 4 weeks.
Ultomiris
Indication: Paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS).
Administration: Intravenous infusion
Infusion Duration: Initial loading dose varies; maintenance every 8 weeks.
Frequency: Initial then every 8 weeks.
Vyvgart
Indication: Generalized myasthenia gravis (gMG) in AChR+ adults.
Administration: Intravenous infusion
Infusion Duration: 1 hour.
Frequency: Weekly x4 doses per cycle.
Zemaira (Alpha₁-Proteinase Inhibitor)
Indication: Alpha₁-PI deficiency and emphysema.
Administration: Intravenous infusion after reconstitution
Infusion Duration: Approx. 15 minutes for a 75 kg patient.
Frequency: Once weekly.